Related MeSH Hierarchy (4)
Chemicals and Drugs [D] » Heterocyclic Compounds [D03] » Alkaloids » Opiate Alkaloids » Morphinans » Naloxone » Naltrexone
Chemicals and Drugs [D] » Heterocyclic Compounds [D03] » Heterocyclic Compounds, Bridged-Ring » Morphinans » Naloxone » Naltrexone
Chemicals and Drugs [D] » Heterocyclic Compounds [D03] » Heterocyclic Compounds, Fused-Ring » Heterocyclic Compounds, 4 or More Rings » Morphinans » Naloxone » Naltrexone
Chemicals and Drugs [D] » Polycyclic Compounds [D04] » Polycyclic Aromatic Hydrocarbons » Phenanthrenes » Morphinans » Naloxone » Naltrexone
Description
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. MeSH
Hierarchy View
Phase 4 Indicated Drugs (3)
Phase 2 Indicated Drugs (3)
Phase 1 Indicated Drugs (1)
Hierarchy Tree View
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
